

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>GROOPMAN JEROME</u>  (Last) (First) (Middle) <u>C/O ONCONOVA THERAPEUTICS, INC.</u> <u>375 PHEASANT RUN</u>  (Street) <u>NEWTOWN PA 18940</u>  (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> <u>07/24/2013</u>	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>Onconova Therapeutics, Inc. [ ONTX ]</u>  <b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b> <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>  <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
--	---	---	---

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to purchase)	02/01/2012	02/01/2022	Common Stock	375	6.13	D	
Stock Option (right to purchase)	12/19/2012	12/20/2022	Common Stock	375	13.28	D	
Stock Option (right to purchase)	02/01/2014	02/02/2023	Common Stock	3,000	13.28	D	
Stock Option (right to purchase)	(1)	02/02/2023	Common Stock	18,754	13.28	D	
Stock Option (right to purchase)	04/25/2013	04/26/2023	Common Stock	375	14.74	D	
Stock Option (right to purchase)	05/14/2013	05/15/2023	Common Stock	375	14.74	D	

**Explanation of Responses:**

1. This option, representing a right to purchase a total of 18,754 shares of Common Stock, is immediately exercisable and vests over 4 years from February 1, 2013, with 25% vesting on February 1, 2014 and 75% vesting in 36 equal monthly installments thereafter, subject to continued service to the Issuer through each vesting date.

**Remarks:**

Two of Two.

/s/ Ajay Bansal, as attorney in fact 07/24/2013

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.